ClinicalTrials.gg
CompletedNCT07036861Updated Jun 25, 2025

A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension

A Phase 1 interventional study of Ibuprofen 2% and Ibuprofen 4% in Healthy Male and Female Subjects, sponsored by Berlin-Chemie AG Menarini Group. Completed at 2 sites in Lithuania. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Berlin-Chemie AG Menarini Group (part of Menarini Group) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Nov 2023, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Purpose of the study is to compare three different formulations of Ibuprofen oral suspension (liquid taken by mouth) to see if there are any differences in how much of the active substance and how quickly it was taken up by by the body, broken down, and how quickly it was removed from the body.

Read the detailed description

In this Phase 1 study, two test medications (reformulated Ibuprofen 2% oral suspension and Ibuprofen 4% oral suspension) were compared with the reference medication (Ibuprofen 4% oral suspension marketed under the trade name Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension) in terms of bioequovalence of the tested formulations.

02

Conditions studied

  • Healthy Male and Female Subjects

Keywords

  • Ibuprofen oral suspension
  • Nurofen oral suspension
  • Bioequivalence study
03

In context

Lead sponsor

Berlin-Chemie AG Menarini Group is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of understanding the form (ICF) and giving signed informed consent which includes compliance with the requirements and restrictions as listed in the ICF and the study protocol.
  2. Healthy male and female subjects aged 18 to 45 years inclusive at the time of ICF signature.
  3. Healthy as determined by an Investigator based on the results of the standard clinical, laboratory and instrumental methods of examination.
  4. Body weight ≥ 50 kg and (BMI) between ≥ 18.5 and ≤ 30 kg/m2.
  5. Non-smokers (for at least 3 months before screening) verified by a cotinine test at screening.
  6. A negative urine pregnancy test (rapid test) within 24 hours before the first IMP dose for female subjects of .

    (no menses for at least 1 year) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) female subjects are exempted from this requirement.

  7. Subjects with preserved agree to use, with their partner, adequate throughout the study and for 15 days thereafter (contraceptive methods with reliability greater than 90%: cervical caps with spermicide, diaphragms with spermicide, condoms with intravaginal spermicide, oral, injectable, transdermal or implanted hormonal contraceptives, vaginal contraceptive ring, non-hormonal intrauterine devices), or true sexual abstinence.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of allergies.
  2. Known or intolerance to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs), fructose and/or any of the IMP.
  3. History of bronchospasm, asthma, rhinitis, angioedema or urticaria associated with the intake of acetylsalicylic acid or other NSAIDs.
  4. History or presence of significant cardiovascular (including congestive heart failure ( IV), arterial hypertension, established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease), pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, infectious, dermatologic, neurologic, or psychiatric disease.
  5. History of recurrent peptic ulcer or gastrointestinal bleeding (>2 distinct episodes of proven ulceration or bleeding) or history of gastrointestinal bleeding or perforation related to previous NSAID therapy.
  6. Cerebrovascular or other active bleeding.
  7. Acute infectious diseases of any organ system (including e.g., influenza, COVID-19, acute respiratory viral infections) less than 4 weeks before the first IMP dose.
  8. History or presence of any other disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  9. History of major abdominal surgery or minor abdominal surgery within 3 months before the first IMP dose.
  10. Clinically significant deviations from the normal parameters (see study protocol Appendix 2 for guidance) in clinical blood count analysis, biochemical blood analysis, urinalysis.
  11. Systolic blood pressure measured in a supine position \< 100 mmHg or > 130 mmHg and/or diastolic blood pressure \< 60 mmHg or > 89 mmHg.
  12. Heart rate \< 60 or > 100 beats per minute.
  13. Female subjects who were attempting to conceive, pregnant or lactating.
  14. Positive test results for or (HBsAg, anti-HBc) or (anti-HCV) or syphilis at screening.
  15. Positive screen for drugs of abuse or alcohol at screening.
  16. Positive test result for cotinine in urine at screening.
  17. Known or suspected drug or alcohol abuse as judged by the Investigator.
  18. Alcohol consumption more than 10 units of alcohol a week (1 unit = 200 mL of dry wine or 50 mL of strong alcoholic drinks or 500 mL of beer) within 6 months before the first IMP dose.
  19. Intake of methylxanthine containing substances (e.g., coffee, tea, chocolate, cocoa, energy drinks, cola) as well as citrus fruits and cranberry (including juices, fruit drinks, etc.) within the last 24 h before the first IMP dose.
  20. Intake of medications that had a significant effect on circulatory dynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, NSAIDs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, diuretics, etc.) within the 2 months before the first IMP dose.
  21. Use of any prescribed or nonprescribed medication, herbal remedies, vitamins and minerals within the 2 weeks before the first IMP dose or longer (at least 5 elimination half-lives) if the medication has a long half-life.
  22. Mental, physical and other reasons that did not allow the subjects according to Investigator's opinion to assess their behavior adequately, to follow correctly the requirements of the clinical study protocol and to assess the expected risks and possible discomfort.
  23. Dehydration (e.g. due to diarrhea, vomiting, or other causes) within the last 48 h before the first IMP dose.
  24. Subjects who had been on a special diet (for whatever reason, e.g., vegetarians or hypocaloric diet [\< 1000 kcal/day]) within the 28 days before the first IMP dose.
  25. Plasma donation within 1 month of screening or blood donation/blood loss >500 mL within the 3 months before screening.
  26. Unwillingness or inability to follow the procedures and restrictions outlined in the protocol and the ICF.
  27. Participation in another clinical study within the 3 months before the first IMP dose in this study.
  28. Female subjects with , having unprotected sexual intercourse with any unsterilized male partner (i.e., a man who is not sterilized by vasectomy for at least 6 months) within the 30 days before the first IMP dose.
  29. Any reason in the opinion of the Investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Ibuprofen 2% oral suspension (T1), reformulated

    400 mg to be taken with a graded syringe

    Drug: Ibuprofen 2%

  • Experimental
    Ibuprofen 4% oral suspension (T2), reformulated

    400 mg to be taken with a graded syringe

    Drug: Ibuprofen 4%

  • Active comparator
    Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension, Reckitt-Benckiser (Poland) S.A.

    400 mg to be taken with a graded syringe

    Drug: Ibuprofen 4%

Interventions

  • Reformulated Ibuprofen 2% oral suspension (Berlin-Chemie AG)

  • Reformulated Ibuprofen 4% oral suspension (Berlin-Chemie AG)

  • Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension (Polish brand name)

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum plasma concentration

    Time frame: 24 hours

  2. AUC0-t

    Area under the curve

    Time frame: 24 hours

  3. tmax

    Time to maximum plasma concentration

    Time frame: 24 hours

Secondary outcomes

  1. AUC0-inf

    Area under the curve to infinity

    Time frame: 24 hours

  2. Residual area

    Time frame: 24 hours

  3. λz

    elimination constant

    Time frame: 24 hours

  4. t1/2

    Half-life

    Time frame: 24 hours

Other outcomes

  1. Safety evaluation

    Incidence and type of Adverse Events (AEs)

    Time frame: 45 days

  2. Safety evaluation

    Proportion of subjects with treatment-related adverse events

    Time frame: 45 days

  3. Safety evaluation

    Proportion of subjects experiencing Serious Adverse Events (SAEs)

    Time frame: 45 days

  4. Safety evaluation

    Proportion of subjects with treatment-related SAEs

    Time frame: 45 days

  5. Safety evaluation

    Proportion of subjects discontinued from the study due to AEs

    Time frame: 45 days

07

Study locations

2 sites
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, 08661, Lithuania
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, LT-08661, Lithuania
08

References and documents

Related links

Individual participant data

Plan to share: No — No publication in an ICMJE journal is planned

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Apr 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 25, 2025
StartActual
Nov 6, 2023
Primary completionActual
Apr 8, 2024
CompletionActual
Jan 31, 2025
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07036861
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Nov 6, 2023
Primary completion
Apr 8, 2024
Completion
Jan 31, 2025
Last update
Jun 25, 2025

Study contacts

Greta Burneikaitė, MD, PhD
principal investigator · Vilnius University Hospital Santaros Klinikos

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion